user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 20267 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.

Dendreon Posts Wider Than Expected Q4 Loss, But Revenues Up YoY (DNDN)

Published on Tue, 03/01/2011 - 17:25
By Stephanie Shyu
cancer, ceo, dendreon, disease, dndn, earnings, eps, health, income, loss, market, medical, mitchell gold, nasdaq, patients, quarter, revenues, shares, stock

Dendreon (NASDAQ:DNDN) reported Q4 and FY 2010 earnings results Tuesday during the trading day, posting a disappointing loss of $0.64 per share for the quarter, a bigger loss than the $0.49 analysts were projecting on average. Net loss for the year was $439.5 million, or $3.18 per share versus a loss of $2.04 per share in 2009.

Revenue for the quarter was $25 million, compared to $21,000 for the same quarter in 2009. FY revenue came in at $48.1 million, compared to $100,000 the year before.

Mitchell H. Gold, M.D., president and chief executive officer, said, "As we look to 2011, it will be a year of both execution and a year of growth for Dendreon, all of which is designed with a single goal in mind: to help patients with cancer live longer and live better lives."

By Stephanie Shyu
sshyu@fnno.com

Most Popular Video News